Loading...
Biological drug therapy for ocular angiogenesis: Anti‐VEGF agents and novel strategies based on nanotechnology
Currently, biological drug therapy for ocular angiogenesis treatment is based on the administration of anti‐VEGF agents via intravitreal route. The molecules approved with this purpose for ocular use include pegaptanib, ranibizumab, and aflibercept, whereas bevacizumab is commonly off‐label used in...
Na minha lista:
| Udgivet i: | Pharmacol Res Perspect |
|---|---|
| Main Authors: | , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
John Wiley and Sons Inc.
2021
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7947217/ https://ncbi.nlm.nih.gov/pubmed/33694304 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/prp2.723 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|